Fig. 1.
![Fig. 1. Administration of Mpl ligand or loss of p53 protects mice from lethal myelosuppression. / Survival of p53−/− mice (knockout [KO]; n = 22) and wild-type mice (WT C57BL/6J; n = 15) that were given 50 μg/kg of PEG-rmMGDF immediately after receiving 80 mg/kg carboplatin intravenously and 7.5 Gy TBI. Control groups of the same sizes were given carrier (1% normal mouse serum in PBS) instead of PEG-rmMGDF.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/7/10.1182_blood.v98.7.2084/5/h81911609001.jpeg?Expires=1735595868&Signature=jHi2N5RnfFZ0kbZs9HxFHpwSEcBU8tmUWzGULcov7awuSKP~b50tzc4km-FmFRwZJkuL0bws~f8xivJpxVg~VwsBY-NxCiaLdFPxeLxRyEj4g5OmMdmL9boktOt4csdPuPxqkZNRR-pugqAm~BwN4LzODW5wJbAnwr7xu0Y4MJCdkx5ZYJ723PNVMFii1LS7csAgCBuCfUxk6kw76-JeQQAkPY8rDOQu42ZtdhPl~1RPtoYrbjtWdTTwrGKV2uYVSQxxfMD4-xcurCsgv6q-JBsVgXLA52G-4R1uu22W5iSttc5VXedJzyPzG5gMoQ0FfE2l9BVAE0ABq2KXcfTdtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Administration of Mpl ligand or loss of p53 protects mice from lethal myelosuppression.
Survival of p53−/−mice (knockout [KO]; n = 22) and wild-type mice (WT C57BL/6J; n = 15) that were given 50 μg/kg of PEG-rmMGDF immediately after receiving 80 mg/kg carboplatin intravenously and 7.5 Gy TBI. Control groups of the same sizes were given carrier (1% normal mouse serum in PBS) instead of PEG-rmMGDF.
